Research
Hormonal
GLP-1 receptor agonists and related incretin-based therapies are effective pharmacological interventions for obesity and type 2 diabetes, offering superior weight loss and cardiovascular benefits compared to previous treatments.
GLP-1 receptor agonists are a major advance in obesity treatment, offering significant weight loss and cardiovascular benefits. They work by mimicking gut hormones that regulate appetite and blood sugar. Consult a doctor to see if they are appropriate for you.
StrongSupportsVERY_HIGH confidence
More recently developed anti-obesity therapies promise to overcome previous concerns about low effect size and safety concerns [6,21–28].
Why this rating
Cites multiple clinical outcome trials and approved drugs.
Source
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Erind Gjermeni · MDPI (MDPI AG) · 2021
narrative_reviewCited 94×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →